---
title: "daratumumab"
slug: "daratumumab"
date: "2024-02-20"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自：[[treatment of amyloidosis]]

# daratumumab

- CD38 蛋白結合的 IgG1κ 人類單株抗體(mAb)
- [Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | NEJM](https://www-nejm-org.autorpa.kfsyscc.org/doi/full/10.1056/NEJMoa2028631)

> 他的中文很妙：兆科

[[daratumumab 健保規範.md|Daratumumab 健保規範]]

- Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression.
- 在新診斷的 → AL 澱粉樣變性患者中，在硼替佐米、環磷醯胺和地塞米松的 → 基礎上加用 daratumumab 與更高的 → 血液學完全緩解頻率和 ✖ 無主要器官惡化或血液學進展的 → 生存率相關。

- Mechanism:
  - Binds to **CD38**
- Dosing: 16 mg/kg IV, dosing interval varies from once weekly to every 4 wks
- PK/PD: T1/2 ∼18 d
- AEs:
  - Fatigue,
  - lymphocytopenia,
  - neutropenia,
  - thrombocytopenia,
  - infusion rxn,
  - fever,
  - upper respiratory sxs,
  - herpes zoster
- DDI:
  - No known pathways of metabolism
- Clinical pearls:
  - Requires premedications before & after the infusion,
  - antiviral ppx should be started w/in 1 wk of tx & continued for 3 mos post tx,
  - interferes w/ RBC antibody screening & cross-matching
